Moss, 9 February 2024

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the fourth quarter and full year 2023.

Highlights

Sales of MNOK 37.5 in 4Q23, up 34% vs 4Q22 (23% organic growth). Full year sales
of MNOK 135.2 in 2023, up 33% vs 2022 (21% organic growth)

EBITDA of NOK -1.0 million in 4Q23 versus NOK -1.5 million in 4Q22.
Irregularities related to raw materials resulted in an increased COGS estimated
to NOK 1.8 million in 4Q23. EBITDA for the full year 2023 of NOK 3.3 million,
compared to NOK -13.0 million in 2022

Year-end cash position at NOK 87.6 million, up NOK 6.0 million compared to
year-end 2022

Cystatin C sales increased 49% in 4Q23 compared to 4Q22 and 41% in 2023 vs 2022

Third party sales increased 96% in 4Q23 compared to 4Q22 and 67% in 2023 vs 2022

Optimisation of the NT-proBNP prototype continues with noteworthy progress in
4Q23 and preparations for production scalability experiments were initiated 

Webcast

Gentian's CEO Hilja Ibert and CFO Njaal Kind will present the results today at
09.00 am, followed by a Q&A session. Join the webcast and submit questions via
the following link:

https://attendee.gotowebinar.com/register/2787750596465033558

The webcast will be available on the company website after the presentation. 

IR contact:

Njaal Kind, CFO and COO
njaal.kind@gentian.no 
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Njaal Kind, CFO at Gentian
Diagnostics ASA, on 9 February 2024 at 08:00 CET.


About Gentian
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures
high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies
within immunochemistry, specifically infections, inflammations, kidney failures
and congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is based in
Moss, Norway, serving the global human and veterinary diagnostics markets
through sales and representative offices in Sweden, USA and China. For more
information, please visit www.gentian.com.